FONTEM-VENTURES
30.5.2019 08:02:07 CEST | Business Wire | Press release
Fontem Ventures, owner of vapour brand blu, today calls on the World Health Organisation (WHO) to recognise the growing evidence that vaping can make a significant contribution to tobacco harm reduction, ahead of World No Tobacco Day 2019 on May 31st .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190529005659/en/
“Currently more than half the world’s population live in countries where vaping is either banned or exists in a regulatory grey area.” said Dr Nveed Chaudhary, Scientific & Regulatory Affairs Senior Manager at Imperial Brands, parent company of Fontem Ventures. “We believe the WHO could help by recognizing the science underlying tobacco harm reduction and the potential health benefits to millions of smokers by opening up new options to switch away from combustible tobacco.”
In countries like the US where vaping is recognised as an alternative for smokers, and vaping products are widely available, data shows smoking rates are falling rapidly1 .
“We are encouraged by China’s recent decision to create a products standards based regulatory framework for vaping2 , which would potentially enable hundreds of millions of smokers to access an alternative to combustible tobacco.” said Dr Chaudhary.
China, India and Indonesia combined have more than 430 million daily smokers, nearly 50% of the world’s total smoking population3 .
Article 1(d) of the WHO’s Framework Convention on Tobacco Control (FCTC) defines tobacco control as “a range of supply, demand and harm reduction strategies that aim to improve the health of a population by eliminating or reducing their consumption of tobacco products and exposure to tobacco smoke.”
E-vapour products contain no tobacco4 , and peer reviewed scientific evidence5 suggests that switching to e-vapour products will substantially reduce exposure to harmful toxicants6 found in combustible tobacco smoke.
About Fontem Ventures
Fontem
Ventures
BV, is the e-vapour business behind blu
.
Headquartered in Amsterdam, Fontem Ventures’ purpose is to drive
electronic vaping technology forward, delivering a better alternative to
smokers and vapers around the world. Fontem Ventures is a subsidiary of
Imperial Brands plc.
1
https://www.cnbc.com/2018/11/08/cdc-says-smoking-rates-fall-to-record-low-in-us.html
2
https://ecigintelligence.com/china-issues-new-industry-standards-for-e-cigarettes-and-e-liquids/
(Subscription only)
3
https://files.tobaccoatlas.org/wp-content/uploads/2018/03/TobaccoAtlas_6thEdition_LoRes.pdf
4
https://www.blu.com/en/US/explore/explore-vaping/e-liquid/what-is-an-eliquid.html
5
Article 14 The WHO FCTC states that “each Party shall develop and
disseminate appropriate, comprehensive and integrated guidelines based
on scientific evidence
and best practices, taking into account
national circumstances and priorities, and shall take effective measures
to promote cessation of tobacco use and adequate treatment for tobacco
dependence” The body of scientific evidence supporting the harm
reduction potential of vaping is now significant and a useful summary
can be found here: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/457102/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf
6
http://www.fontemscience.com/research/library/evaluation-of-the-safety-profile-of-an-electronic-vapour-product-used-for-two-years-by-smokers-in-a-real-life-setting/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005659/en/
Contact:
Press Contact James Campbell Senior Communications Manager Fontem Ventures B.V. james.campbell@blu.com +31 61 442 6896
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
